CASI Pharmaceuticals (CASIF) Finished Goods (2024 - 2025)
CASI Pharmaceuticals' (CASIF) quarterly Finished Goods came in at $840000.0 in Q4 2025, down 84.01% YoY from $5.3 million in Q4 2024, and down 84.01% on a QoQ basis from $5.3 million in Q4 2024.
CASI Pharmaceuticals (CASIF) Finished Goods (2024 - 2025) Analysis & Trends
CASI Pharmaceuticals (CASIF) has 2 years of Finished Goods data on file, last reported at $840000.0 in Q4 2025.
- Quarterly Finished Goods fell 84.01% year-over-year to $840000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $840000.0 (down 84.01% YoY) and the FY2025 annual result came in at $840000.0, down 84.01% from the prior year.
- Finished Goods retreated to $840000.0 in Q4 2025, from $5.3 million in the prior quarter.
- In the past five years, Finished Goods ranged from a high of $5.3 million in Q4 2024 to a low of $840000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | CASI Pharmaceuticals | 2.65 Mn | -3.76 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 840,000.00 |
| Dec 31, 2024 | 5.25 Mn |